Local Entrepreneurs Bring AtWork to Indiana's Capital, Connecting Job Seekers and Employers
By GlobeNewswire Published on June 13, 2025, 17:30 IST
INDIANAPOLIS, June 13, 2025 (GLOBE NEWSWIRE) — AtWork , the nation's leading staffing franchise for empowering job seekers and facilitating company growth, has opened its newest location in northwest Indianapolis at 4150 Lafayette Road in the shopping center next to the Royal Motors Group.
AtWork Indianapolis Northwest is locally owned by longtime family friends, Adam Turner and Patrick Bugbee. Turner brings years of business ownership experience, having previously sold hotel franchises for Wyndham Worldwide and owned multiple GNC retail locations. In addition, Bugbee brings over a decade of managerial experience to the table, having worked as an Area Manager for Mattress Firm. As residents of the area for many years, Turner and Bugbee possess a thorough understanding of the local job market and the distinct needs that businesses and job seekers in the area might have.
'Patrick and I have been friends for years, and we both found ourselves looking for career and lifestyle changes at the same time,' said Turner. 'AtWork's model of treating both candidates and clients with care is exactly what drew us to this opportunity. There's a real need for qualified talent support in Indianapolis, and we're eager to fill that gap with personalized, hands-on staffing solutions. We want job seekers and businesses here to know that when they reach out to AtWork Indianapolis Northwest, they'll receive a personal response and clear next steps from me or Patrick.'
For more than three decades, AtWork's mission has been to connect people with jobs and jobs with people. With more than 100 locations nationwide, AtWork puts nearly 40,000 individuals to work each year in administrative, light-industrial, accounting and finance, hospitality, IT and management-level positions at some of the nation's largest and most recognizable companies.
'We're proud to expand into Indiana with the opening of our Indianapolis location, offering a trusted resource where job seekers and businesses can find the staffing solutions they need to succeed and flourish,' said Jason Leverant, President and COO of AtWork. 'AtWork Indianapolis Northwest will serve as a key resource to help employees thrive and businesses prosper. Adam and Patrick are the perfect partners to champion our mission and be servant leaders in their local community.'
AtWork Indianapolis Northwest is located at:4150 Lafayette RoadIndianapolis, IN 46254
(317) 406-7274
For more information, visit AtWork.com .
###
ABOUT ATWORK:
Headquartered in Knoxville, Tennessee, AtWork is an award-winning staffing franchise with over 100 locations worldwide. Recognized by Franchise Business Review as a Top 200 Franchise; Entrepreneur® as a Top 500 and Top Franchise for Diversity, Equity and Inclusion; Franchise Times Top 400 Franchise; Staffing Industry Analyst as the Best Staffing Firms to Work for; and as Clearly Rated's Best of Staffing® for Client Satisfaction and Talent Satisfaction, AtWork can staff an entire production facility or provide temporary help around the office. For more than 30 years, leading companies from across the nation have trusted AtWork to recruit the best talent. AtWork has all of your staffing needs covered. To learn more about our services, visit AtWork.com .
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Endo Tools Therapeutics and Fujifilm Middle East FZE Partner to Extend Access to Innovative Treatments for Obesity
GOSSELIES, Belgium & DUBAI, United Arab Emirates--(BUSINESS WIRE)--Endo Tools Therapeutics (ETT), a company developing and marketing advanced endoscopic medical devices, and Fujifilm Middle East FZE, a subsidiary of FUJIFILM Holdings Corporation, today announce their strategic partnership, to enable patients living with obesity in the Middle East and Africa to access a novel endoscopic treatment through ETT's endomina® platform. The platform enables endoscopists to perform a volume reduction of the stomach using a minimally invasive procedure performed via oral entry. "Endo Tool Therapeutics' partnership with Fujifilm is a key strategic step in our international expansion. Fujifilm's extensive network and deep knowledge of the region make it an ideal partner to bring the benefits of endomina to a broader patient population increasingly affected by obesity," said Alexandre Chau, CEO of Endo Tools Therapeutics. It was estimated that worldwide the number of people living with obesity had reached 890 million in 2022, a figure that has doubled over the last 30 years. In the Middle East, the prevalence of obesity is 21.2%. Obesity contributes to increased risks of comorbidities such as diabetes, cardiovascular disease and certain cancers; high rates pose serious socio-economic and health system challenges in the region 1. 'We are excited to bring new, minimally invasive solutions like endomina into our portfolio. Offering innovative treatment options for patients living with obesity reflects our ongoing commitment to advancing patient care and outcomes across the region,' said Atsushi Tateishi, General Manager of Fujifilm Middle East FZE. 'Through this collaboration, we aim to make meaningful advances in obesity care and improve access to cutting-edge therapies for healthcare providers and patients alike.' About Fujifilm Middle East FZE Fujifilm Middle East & Africa, located in Dubai, is a subsidiary of FUJIFILM Holdings Corporation, Tokyo, Japan. Fujifilm was founded in 1934 as a producer of photographic film under the name Fuji Photo Film Co. Ltd. The company has built up a wealth of advanced technologies in the field of photo imaging, and in line with its efforts to become a comprehensive healthcare company, Fujifilm is now applying these technologies to the prevention, diagnosis and treatment of diseases in the medical and life science fields. Fujifilm MEA performs its operations in medical systems, graphic systems, device technology, electronic imaging, photo imaging, optical devices, recording media and industrial products in various offices throughout the Middle East & Africa. About Endo Tools Therapeutics Located in Gosselies, Belgium, Endo Tools Therapeutics S.A. (ETT) offers a portfolio of advanced, incisionless and minimally invasive endoscopic medical devices. The company's mission is to develop solutions that expand the range of gastrointestinal procedures that can be performed using standard gastroscopes. By developing minimally invasive treatment solutions, ETT aims to reduce the number of complications, and the length of hospital stay for patients, and in doing so improve their comfort. The initial results from bariatric procedures performed using ETT's soft tissue approximation devices have been published in multiple scientific articles, e.g. GIE in 2017, Endoscopy in 2018, Gut in 2020, EIO in 2022 and GIE in 2024. Moreover, endomina is included in the joint ASGE-ESGE guideline on primary endoscopic bariatric and metabolic therapies. To date, over 1,200 gastroplasty procedures have been performed using Endo Tools Therapeutics' devices across Europe, the US and the Middle East. In Europe the devices are approved for use in endoscopic gastroplasty procedures for the treatment of obesity, while in the US they are cleared for placement of sutures and approximation of soft tissue in the gastrointestinal tract.
Business Wire
an hour ago
- Business Wire
RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development (AMED)
SENDAI, Japan--(BUSINESS WIRE)--RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called ai Protein ® has announced its participation in a research and development program funded by a government grant of 54 million JPY (approximately US$372K for the first year) from the Japanese Agency for Medical Research and Development (AMED). This project, set to continue over 4 years, is led by Prof. Mitsuo Umetsu of Tohoku University, who also serves as RevolKa's Chief Scientific Officer. This opportunity will further accelerate RevolKa's rare disease drug discovery and development efforts, previously announced on July 30 th, 2024. ( RevolKa's core technology, ai Protein ®: a robust directed protein evolution platform integrated with AI (artificial intelligence) creates exceptionally high performance proteins, going beyond natural evolution and offering advantages for therapeutic strategies. ai Protein ® has generated many successful outcomes with many partner companies. About ai Protein ® Technology RevolKa's proprietary technology, ai Protein ® is an AI-assisted directed evolution platform for proteins. Naturally occurring proteins are linear polymers composed of amino acids and their derivatives, folding into a tertiary structure through internal complex atomic interactions to exhibit biological functions. Proteins have evolved their biological functional complexity over hundreds of millions of years. However, the relationship between protein sequence, structure, and function remains poorly understood to enable rational design of protein sequences for specific function. RevolKa's AI engine is trained with sequence-function relationship data, enabling statistical prediction of optimized protein sequences with desired functions. Furthermore, ai Protein ® can evolve multiple properties simultaneously. This technology is a powerful and cost-effective solution for creating novel and highly functional proteins suitable for pharmaceutical and industrial applications. About RevolKa Ltd. RevolKa is a venture-backed biotechnology company founded in April 2021 by academic and industry experts in biotechnology and artificial intelligence. Our mission is to contribute to human well-being by creating novel proteins for therapeutics and industrial applications using our proprietary technology, ai Protein®. The name "RevolKa" is derived from the Latin word for evolution, "evolutio' and the Ainu (an indigenous Japanese people) word for raise, 'reska'. RevolKa's headquarters and laboratories are located in Sendai, Japan. The company's investors include D3 LLC, Tohoku University Venture Partners Co., Ltd., DEEPCORE Inc., and SBI Investment Co., Ltd. For more information, visit
Business Wire
3 hours ago
- Business Wire
CARMAT Announces Filing Today for Insolvency and Requesting Being Placed in Receivership
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces filing for insolvency 1 and requesting to be placed in receivership 2 to the Versailles Economic Affairs Court 3, as well as the suspension of CARMAT shares trading, starting June 30, 2025, before stock market opening. Insolvency filing and request to be placed in receivership On June 20, 2025, CARMAT announced in a press release being at risk of insolvency as early as the end of June 2025 unless managing before then, to secure additional cash of at least €3.5 million. Despite its continued efforts, the Company has not managed at this stage, to secure neither additional cash nor new financing. Given this, the Company will today file for insolvency and request to be placed in receivership to the Versailles Economic Affairs Court ('the Court'). The Court will rule on this request, following a hearing expected in the coming days. As a reminder, according to its current business plan and assuming 'business as usual' situation, the Company estimates its funding requirements over the next 12 months at approximately €35 million, including approximately €20 million by the end of December 2025. Suspension of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR) Pending the Court's decision, CARMAT has asked Euronext to suspend the trading of its shares starting on June 30, 2025, before the stock market opens. The Company anticipates this suspension to be lifted once the Court's decision has been rendered and communicated to the market. Next steps Pending the Court's decision, CARMATS's operations carry-on and the Company continues to actively explore all options to ensure the continuation of its business activities. The Company believes that the opening of a receivership procedure would be the most appropriate framework to facilitate this continuation. More generally, whatever the Court's decision, the Company will endeavor to provide continuous support to patients who currently benefit from its Aeson® artificial heart. Press releases will be issued regularly as the Company's situation evolves and the proceedings progress. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway extends only until the end of June 2025, and that CARMAT is therefore facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).
